Alemtuzumab Biosimilar, Human CD52 Monoclonal Antibody

Alemtuzumab Biosimilar uses the same protein sequences as the therapeutic antibody alemtuzumab. Alemtuzumab is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein. It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human CD52, a protein present on the surface of mature lymphocytes.
Clone	Alemtuzumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	146.06 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.4